PMID- 37781391
OWN - NLM
STAT- MEDLINE
DCOM- 20231003
LR  - 20231003
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy 
      of cancer.
PG  - 1240275
LID - 10.3389/fimmu.2023.1240275 [doi]
LID - 1240275
AB  - Immune checkpoint blockade is a compelling approach in tumor immunotherapy. 
      Blocking inhibitory pathways in T cells has demonstrated clinical efficacy in 
      different types of cancer and may hold potential to also stimulate innate immune 
      responses. A novel emerging potential target for immune checkpoint therapy is 
      leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1). LILRB1 
      belongs to the superfamily of leukocyte immunoglobulin-like receptors and exerts 
      inhibitory functions. The receptor is expressed by a variety of immune cells 
      including macrophages as well as certain cytotoxic lymphocytes and contributes to 
      the regulation of different immune responses by interaction with classical as 
      well as non-classical human leukocyte antigen (HLA) class I molecules. LILRB1 has 
      gained increasing attention as it has been demonstrated to function as a 
      phagocytosis checkpoint on macrophages by recognizing HLA class I, which 
      represents a 'Don't Eat Me!' signal that impairs phagocytic uptake of cancer 
      cells, similar to CD47. The specific blockade of the HLA class I:LILRB1 axis may 
      provide an option to promote phagocytosis by macrophages and also to enhance 
      cytotoxic functions of T cells and natural killer (NK) cells. Currently, LILRB1 
      specific antibodies are in different stages of pre-clinical and clinical 
      development. In this review, we introduce LILRB1 and highlight the features that 
      make this immune checkpoint a promising target for cancer immunotherapy.
CI  - Copyright (c) 2023 Zeller, Munnich, Windisch, Hilger, Schewe, Humpe and Kellner.
FAU - Zeller, Tobias
AU  - Zeller T
AD  - Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, 
      University Hospital, LMU Munich, Munich, Germany.
FAU - Munnich, Ira A
AU  - Munnich IA
AD  - Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, 
      University Hospital, LMU Munich, Munich, Germany.
FAU - Windisch, Roland
AU  - Windisch R
AD  - Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, 
      University Hospital, LMU Munich, Munich, Germany.
FAU - Hilger, Patricia
AU  - Hilger P
AD  - Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, 
      University Hospital, LMU Munich, Munich, Germany.
FAU - Schewe, Denis M
AU  - Schewe DM
AD  - Medical Faculty, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
FAU - Humpe, Andreas
AU  - Humpe A
AD  - Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, 
      University Hospital, LMU Munich, Munich, Germany.
FAU - Kellner, Christian
AU  - Kellner C
AD  - Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, 
      University Hospital, LMU Munich, Munich, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230913
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Leukocyte Immunoglobulin-like Receptor B1)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunoglobulins)
RN  - 0 (LILRB1 protein, human)
RN  - 0 (Antigens, CD)
SB  - IM
MH  - Humans
MH  - Leukocyte Immunoglobulin-like Receptor B1/metabolism
MH  - *Neoplasms
MH  - Macrophages
MH  - *Antineoplastic Agents
MH  - Histocompatibility Antigens Class I
MH  - Killer Cells, Natural
MH  - Immunoglobulins/metabolism
MH  - Antigens, CD/metabolism
PMC - PMC10533923
OTO - NOTNLM
OT  - LILRB1 (ILT2)
OT  - NK cells
OT  - T cells
OT  - antibody therapy
OT  - cancer
OT  - immune checkpoint blockade
OT  - macrophages
OT  - phagocytosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/10/02 06:42
MHDA- 2023/10/03 06:47
PMCR- 2023/01/01
CRDT- 2023/10/02 04:44
PHST- 2023/06/14 00:00 [received]
PHST- 2023/08/08 00:00 [accepted]
PHST- 2023/10/03 06:47 [medline]
PHST- 2023/10/02 06:42 [pubmed]
PHST- 2023/10/02 04:44 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1240275 [doi]
PST - epublish
SO  - Front Immunol. 2023 Sep 13;14:1240275. doi: 10.3389/fimmu.2023.1240275. 
      eCollection 2023.